Back to today’s briefing

Story perspectives

China's Biotech Dominance Grows Amid U.S. Restrictions

12/26/2025

38 5 Full Breakdown

Summary

Story summary

In 2025, China's influence in the biotech sector grew, as Mark Lansdell of Evaluate reported 142 licensing and acquisition agreements, up from 134 in 2024, with a total potential value of $92.2 billion.
Early 2025 saw China accounting for 32% of the value of outlicensing deals.
The U.S. Biosecure Act restricts collaboration with certain Chinese firms.
Industry leaders emphasize the need for strategic foresight to navigate these challenges.

1 of 1

Story summary

In 2025, China's influence in the biotech sector grew, as Mark Lansdell of Evaluate reported 142 licensing and acquisition agreements, up from 134 in 2024, with a total potential value of $92.2 billion.
Early 2025 saw China accounting for 32% of the value of outlicensing deals.
The U.S. Biosecure Act restricts collaboration with certain Chinese firms.
Industry leaders emphasize the need for strategic foresight to navigate these challenges.